TTFields for Mesothelioma: Optune Lua

What Are Tumor Treating Fields?

Tumor Treating Fields (TTFields) is an FDA-approved treatment that uses alternating electric fields to disrupt cancer cell division. For mesothelioma, the device is called Optune Lua and is used in combination with standard chemotherapy.

How it works:

• Low-intensity electric fields (200 kHz) are delivered through transducer arrays placed on the skin
• These fields interfere with cancer cell division (mitosis)
• Normal cells are largely unaffected due to their slower division rate
• Treatment is worn continuously for maximum benefit

FDA Approval for Mesothelioma

Optune Lua received FDA approval for malignant pleural mesothelioma in combination with pemetrexed and platinum-based chemotherapy.

This makes TTFields one of the few treatment modalities specifically approved for mesothelioma beyond:

• Chemotherapy (pemetrexed + cisplatin/carboplatin)
• Immunotherapy (nivolumab + ipilimumab)
• Surgery (EPP, P/D)

How TTFields Treatment Works

What Patients Wear Daily

The Optune Lua system has three parts: transducer arrays (adhesive pads placed on the torso), a portable battery pack that allows mobility during treatment, and connection cables linking the arrays to the power source.

Treatment is continuous. Patients wear the device most of the day. Arrays are replaced regularly, and the battery allows normal daily activities. People can work, exercise, and travel while on treatment.

Why Daily Hours Drive Outcomes

Research from glioblastoma studies shows patients with 75% or higher compliance had significantly better outcomes. Higher daily use correlates with improved survival, and the treatment works best when worn consistently.

What the Evidence Shows

Glioblastoma Data (Reference Point)

The most extensive TTFields data comes from glioblastoma treatment (EF-14 trial):

Measure	TTFields + Chemo	Chemo Alone
Median overall survival	20.5 months	15.6 months
2-year survival	43%	29%

This 5-month survival improvement established TTFields as a viable cancer treatment.

Mesothelioma Application

TTFields is approved for mesothelioma based on:

• Mechanism of action applies to all dividing cancer cells
• Combination with standard chemotherapy
• Favorable safety profile
• Ongoing research in people with mesothelioma

Safety Profile

TTFields has a favorable side effect profile compared to systemic treatments:

Common Side Effects

Side Effect	Frequency	Management
Skin irritation	Common	Array repositioning, topical creams
Skin redness	Common	Breaks between array placement
Itching	Common	Antihistamines if needed

Limited Impact Beyond the Skin

TTFields carries minimal systemic toxicity. Unlike chemotherapy, it does not cause nausea, lower blood counts, trigger hair loss, or require hospitalization.

This makes TTFields particularly valuable for patients who cannot tolerate intensive chemotherapy, who want to maintain quality of life during treatment, or who are using it as part of multimodal therapy.

Who Is a Candidate?

TTFields is most appropriate for patients diagnosed with malignant pleural mesothelioma who are receiving or planning pemetrexed-based chemotherapy, who can comply with a continuous treatment schedule, and who do not have a pacemaker or other implanted electronic device.

Before starting, talk with your oncologist about how TTFields fits your overall treatment plan, how it coordinates with surgery, chemo, or immunotherapy, the logistics of continuous wear, and insurance coverage.

Practical Considerations

Daily Life with TTFields

Patients can:

• Work and perform daily activities
• Exercise (with precautions for arrays)
• Shower (with temporary array removal)
• Travel (carry spare batteries)

Patients should:

• Wear the device as many hours as possible
• Keep arrays clean and dry
• Replace arrays on schedule
• Report any skin issues promptly

Support Services

Novocure (the manufacturer) provides:

• Patient support specialists
• Technical assistance
• Insurance navigation help
• Educational materials

Combining TTFields with Other Treatments

TTFields + Chemotherapy

The FDA-approved use combines TTFields with pemetrexed plus cisplatin or carboplatin. This multimodal approach targets cancer through two distinct mechanisms: chemotherapy kills dividing cells directly, while TTFields disrupts cell division through low-intensity electric fields. The combination may produce additive effects because the mechanisms are independent.

TTFields + Immunotherapy

Research is exploring TTFields combined with checkpoint inhibitors:

• May enhance immune response
• Could improve immunotherapy effectiveness
• Clinical trials are investigating these combinations

TTFields + Surgery

For surgical candidates:

• TTFields may be used before or after surgery
• Could help control microscopic disease
• Discuss timing with your treatment team

Current Research

Ongoing Trials

Novocure continues researching TTFields in various cancers:

• Phase 3 TRIDENT trial (glioblastoma, 2026)
• Studies in pancreatic cancer
• Research in non-small cell lung cancer

Mesothelioma Research

Active areas of investigation:

• Optimal duration of treatment
• Best combinations with other therapies
• Biomarkers predicting response
• Long-term outcomes

Questions for Your Doctor

1. Is TTFields appropriate for my mesothelioma stage and type?
2. How does TTFields fit into my overall treatment plan?
3. What compliance level is needed for best results?
4. Are there clinical trials combining TTFields with other treatments?
5. What is the cost and is it covered by my insurance?
6. What support is available for managing the device?

Comparing Treatment Options

Treatment	Administration	Side Effects	Compliance
TTFields	Continuous wear	Skin irritation	High daily use
Chemotherapy	IV infusions	Nausea, fatigue, blood counts	Scheduled cycles
Immunotherapy	IV infusions	Immune-related	Scheduled cycles
Surgery	One-time	Surgical recovery	N/A

TTFields offers a unique approach with minimal systemic effects, making it a valuable addition to the mesothelioma treatment toolkit.